本報道最初發表于Endpoints News。請點擊這里查看原文
Summit Therapeutics released a much-anticipated cut of data in North American and European lung cancer patients on Sunday, trumpeting a new analysis in which its drug ivonescimab, when added to chemotherapy, reduced the risk of death by a statistically significant margin compared to chemo alone.
Summit Therapeutics 周日公布了備受期待的北美與歐洲肺癌患者數據，稱在一項新分析中，其藥物 ivonescimab 聯合化療相比單純化療，在統計學上顯著降低了死亡風險。
您已閱讀5%（421字），剩余95%（7713字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。